Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Sara Torres-Esquius, Maria Gabarros-Subira, Maria Eugenia Rivero, Guillermo Ramil López, Lucia García Mañó, Felix Lopez, Concepción Fernandez, Francesca Guijarro, Marina Díaz-Beyá, Marta Pratcorona Canela, Pamela Acha, Sandra Novoa Jáuregui, Esperanza Tuset, Laura Palomo, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4998.

https://doi.org/10.1182/blood-2025-4998

Published: 2025

Journal Articles

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Sara Torres-Esquius, Maria Gabarros-Subira, Carmelo Gurnari, Carlos Bravo-Perez, Guillermo Ramil López, Raquel De Paz Arias, Alejandro Sanz, Maria Muñoz Martinez, Francisco Beas, Sandra Novoa Jáuregui, Marta Pratcorona Canela, Silvia Saumell, Maria Teresa Voso, Jaroslaw Maciejewski, Pamela Acha, David Valcarcel, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4997.

https://doi.org/10.1182/blood-2025-4997

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 6167.

https://doi.org/10.1182/blood-2024-203130

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies

Sara Torres-Esquius, Guillermo Ramil López, Maria Gabarros Subira, Pamela Acha, Sandra Novoa Jáuregui, Marta Pratcorona, Silvia Saumell, David Valcarcel, Andres Jerez, Maria Julia Montoro

Blood (2024) 144 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2024-194574

Published: 2024

Journal Articles

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2024-204557

Published: 2024

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Helena Castellet, Guillermo Ramil López, Ana Garrido, Alícia Artigas-Baleri, Marta Pratcorona, Olga Salamero, Albert Cortés-Bullich, Susana Vives, Mar Tormo, Martin Mascaro Riera, David Gallardo, Josep Maria Marti Tutusaus, Antonio Garcia, Jorge Sierra, Jordi Esteve, Josep Nomdedeu

Blood (2023) 142 (Supplement 1): 6045.

https://doi.org/10.1182/blood-2023-186064

Published: 2023

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

Journal Articles

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Blood (2019) 134 (Supplement_1): 289.

https://doi.org/10.1182/blood-2019-128682

Published: 2019

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Guadalupe Oñate, MD, Ana Garrido, MD, Jordi Esteve, MD PhD, Rosa Coll, MD, Montserrat Arnan Sangerman, MD, Susana Vives, MD, Antonia Sampol, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD, Maria Paz Queipo De Llano, MD, Antoni Garcia-Guiñon, MD, Joan Bargay, MD PhD, Olga Salamero, MD, Alba Aljarilla, Salut Brunet, MD PhD, Jorge Sierra, MD, Josep Nomdedeu, MD PhD, Marta Pratcorona, MD PhD

Blood (2018) 132 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2018-99-115337

Published: 2018

Journal Articles

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Blood (2017) 130 (Supplement 1): 567.

https://doi.org/10.1182/blood.V130.Suppl_1.567.567

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only